Actually, target monoclonal antibody–mediated neutropenia was reported in a trial with the CD33-specific antibody-drug conjugates gemtuzumab ozogamicin and SGN-33A by directly binding to CD33 on the surface of myeloid progenitor cells (38). The gene discussed is CD33; the disease is neutropenia.